Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC
NCT ID: NCT04459468
Last Updated: 2026-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
17 participants
OBSERVATIONAL
2022-11-04
2025-09-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective, Observational Study of Biomarkers in Liver Cancer - Identification of Actionable Events
NCT01963949
Novel Biomarker Assay for Biomarker Assay for HCC Detection
NCT05494853
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment
NCT01492127
Identification of Liver Fibrosis Biomarkers
NCT06819917
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)
NCT03804593
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The approach is to identify novel proteomic biomarkers for HCC patients treated with Lipiodol TACE, denovo ablation or Y90 using beads-based X-aptamer library, then validate and create a biomarker panel that can be used to predict the outcome of HCC post treatment.
Lipiodol TACE, denovo ablation, or Y90 will be done as standard of care and the only thing done as research will be blood draws pre and post-TACE.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HCC for Lipiodol TACE, denovo ablation, or Y90 radioembolization
These patients will receive standard of care Lipiodol TACE, denovo ablation, or Y90 radioembolization treatment. No research intervention is planned.
Lipiodol
Lipiodol TACE procedure
Healthy controls
Healthy controls from public database
No interventions assigned to this group
HCC patients
HCC patients will be used for biomarker validation.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lipiodol
Lipiodol TACE procedure
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female aged 18-70years.
3. Diagnosed with primary or metastatic liver cancer.
4. Scheduled to undergo Lipoidal TACE, denovo ablation, or Yttrium-90 (Y90) radioembolization as part of standard of care.
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Texas Southwestern Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anil Pillai
ASSOC PROFESSOR - Radiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anil Pillai, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Texas Southwestern Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UT Southwestern Medical Center
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STU-2019-1758
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.